|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Immunological Markers | Summary P-value  (Kruskall-Wallis) | | | Adjusted P-values  (Post-hoc Pairwise Comparison Between  Remission, Active and Control Subjects) | | |
|  | | |  | **Remission**  **v.**  **Active** | **Remission**  **v.**  **Control** | **Active**  **v.**  **Control** |
| **T-cell subsets (%) and ratios in the**  **CD3+CD4+ compartment** | |  | |  |  |  |
| **Treg (CD25+FoxP3+)** | | 0.000\*\*\* | | ↑ 0.000\*\*\* | 0.118 | 0.267 | |
| **TIGIT+Treg** | | 0.000\*\*\* | | ↑ 0.000\*\*\* | 0.661 | 0.126 | |
| **TIGIT+Treg: TIGIT+FoxP3-** | | 0.049\* | | ↑ 0.049\* | 1.000 | 0.219 | |
| **TIGIT+FoxP3+CD25+: TIGIT+FoxP3-** | | 0.003\*\* | | ↑0.002\*\* | 0.111 | 0.091 | |
| **Th1 (Tbet+)** | | 0.025\* | | ↓ 0.024\* | 0.755 | 0.858 | |
| **Th17 (RORγt+)** | | 0.564 | | - | - | - | |
| **Treg: Th1** | | 0.001\*\* | | ↑ 0.001\*\* | 1.000 | ↓ 0.013\* | |
| **Treg: Th17** | | 0.000\*\*\* | | 0.828 | ↑ 0.000\*\*\* | ↑ 0.014\* | |
| **Tbet+Treg** | | 0.000\*\*\* | | ↑ 0.005\*\* | ↑ 0.000\*\*\* | 0.859 | |
| **RORγt+Treg** | | 0.363 | | - | - | - | |
| **Th1/17 (RORγt+ Tbet+ )** | | 0.183 | | - | - | - | |
| **Serum cytokine levels (pg/mL)** | |  | |  |  |  | |
| **IL-10** | | 0.000\*\*\* | | ↑ 0.011\* | 0.082 | ↓ 0.000\*\*\* | |
| **TGF-β** | | 0.001\*\* | | ↑ 0.007\*\* | ↑ 0.004\*\* | 1.000 | |
| **IFN-γ** | | 0.000\*\*\* | | ↓ 0.015\* | 0.130 | ↑ 0.000\*\*\* | |
| **IL-17** | | 0.003\*\* | | ↓ 0.002\*\* | 0.460 | 0.408 | |
| **IL-22** | | 0.002\*\* | | ↓ 0.001\*\* | 0.693 | 0.210 | |
| **CpG site methylation levels (%)** | |  | |  |  |  | |
| **FOXP3 Promoter** | | 0.037\* | | ↓ 0.036\* | 0.405 | 1.000 | |
| **FOXP3 TSDR** | | 0.005\*\* | | ↓ 0.003\*\* | 0.709 | 0.177 | |
| **TIGIT** | | 0.004\*\* | | ↓ 0.003\*\* | 0.850 | 0.120 | |
| **TBX21/ TBET** | | 0.122 | | - | - | - | |
| RORC2/ RORγT | | 0.006\* | | ↑ 0.016\* | 1.000 | ↓ 0.014\* | |